Infuse® Maker, Medtronic, Cutting Staff
Device maker, Medtronic Inc., just announced another scheduled staff cut. We recently wrote that Medtronic was laying off about 4 percent of its spinal business workforce worldwide, which amounted to about 230 of it spinal division’s 5,600 employees,
This is the third year in a row, according to Pioneer Press, that Medtronic has announced cuts. The announcement was made during a conference call and confirmed that the device maker plans on eliminating 2,000 jobs worldwide. About half will impact Medtronic’s workforce in the United States, according to the firm’s chief financial officer, Gary Ellis. Continue reading
da Vinci Robotic Surgery Case With Jury
Jury deliberations are scheduled in the first of some 26 lawsuits brought over Intuitive’s da Vinci robotic surgical system and involve allegations of injuries associated with the controversial robotic system.
Kitsap County Superior Court Judge Jay Roof (Port Orchard, Washington), just handed the case to the 12-member jury after a five-week trial, according to Bloomberg News. Deliberations being this week.
Personal injury lawsuits have alleged that the da Vinci system has caused patients to suffer from a variety of adverse events, including internal injuries. Many of these injuries are the result of burns, tears, and other complications. In some cases, patients have died or suffer from chronic pain, even disability. da Vinci lawsuits fault aggressive Intuitive marketing positioned to induce hospitals to buy the costly system. Lawsuits also allege that a collaboration of design flaws and poor physician training on the da Vinci led to the injuries alleged in the litigation. At last count, some 70 deaths have been tied to the system since 2009. Continue reading
Jurors Told Intuitive Surgical Ran Like a Car Dealership
In a case involving the safety of Intuitive Surgical’s da Vinci robotic system, the jury was told that the company acted “just like a car dealership” in training doctors to use the equipment.
In addition, jurors heard that the plaintiff, Fred Taylor, had died because of the company’s practices, and that Intuitive should pay more than $8 million in damages to his estate. These remarks were part of the plaintiff’s attorney’s closing arguments in a Port Orchard, Washington state court, Bloomberg News reports. Continue reading
End in Sight for Water-Contamination Cleanup at Camp Lejeune
At Camp Lejeune, the North Carolina Marine Corps base, cleanup continues of the decades-long drinking-water contamination problem that began in the 1950s.
More than 600 polluted sites are scattered around the 170-square-mile Marine base, located at the mouth of the New River. About five-dozen sites remain to be cleaned up, according to The Associated Press (AP). The contamination comes from a variety of pollutants – leaking gasoline from the base’s fuel storage farm, and chemicals including carcinogenic pesticides, benzene, and dry-cleaning solvents, some of which were intentionally dumped at Lejeune. Continue reading
Pharmacists Distributed Cheap Drug Substitutes to Kidney Dialysis Patients, Faces Four Years in Prison
A Tennessee pharmacist just pleaded guilty to swapping a cheaper drug substitute for the U.S. Food and Drug Administration (FDA) approved iron sucrose drug for kidney dialysis patients.
The pharmacist, Robert Harshbarger, 53, substituted a cheaper version of the drug from China, which was administered to kidney dialysis patients in Kansas, according to Kansas First News. Harshbarger was conducting business as American Inhalation Medication Specialists, Inc. and pleaded guilty to one count of distributing a misbranded drug and one count of health care fraud. Continue reading
Experimental Sleep Drug, Suvorexant, Raises FDA Concerns
The U.S. Food and Drug Administration (FDA) says that experimental insomnia drug, suvorexant, manufactured by Merck & Co. Inc., may be associated with dangerous side effects.
The experimental insomnia medication was found to be effective at helping patients sleep; however, suvorexant was found to have some significant side effects, such as daytime drowsiness and suicidal ideation, the agency’s advisory committee warned, according to CBS/The Associated Press (CBS/AP). The FDA released a review of suvorexant this week, in advance of today’s public meeting. Continue reading
Hidden Camera Reveals Horrifying Abuse of Canadian Nursing Home Patient
Shocking video footage taken by hidden camera at an Ontario, Canada, nursing home shows an elderly woman being subjected to horrific abuse at the hands of nursing home employees.
Four employees at St Joseph’s at Fleming long-term care home have been suspended pending investigation, the (U.K.) Daily Mail reports, after a patient’s son documented repeated abuse with a hidden camera he placed in his mother’s room. The Ontario Ministry of Health is investigating the case. While Alan Cavell, CEO of St Joseph’s at Fleming, stopped short of calling the treatment seen on camera abuse, “I would think that most people would say that it was,” he told CTV News. Continue reading
Man Alleges Taking Actos for Two Years Caused Bladder Cancer
A South Dakota man is the latest to bring a lawsuit against Takeda Pharmaceuticals, the maker of Type 2 diabetes drug, Actos (pioglitazone). The plaintiff alleges that taking Actos for two years caused him to develop bladder cancer.
Actos was approved by the U.S. Food and Drug Administration (FDA) in 1999.
According to the complaint, the man began taking Actos in January 2009; he developed bladder cancer in May 2011, allegedly due to his having taken Actos. At the time of his diagnosis, he stopped taking the medication. The lawsuit alleges that the defendants were aware that taking Actos could lead to an increased risk of bladder cancer, but failed to disclose this information to the man, his doctor, and consumers. The plaintiff is suing for extensive pain and suffering and severe emotional distress. Continue reading
Parker Waichman LLP Takes on Credit Card Companies, Fights for Small Business
National law firm, Parker Waichman LLP, and co-counsel just filed an objection to the passage of a proposed $7.25 billion settlement of a price-fixing case brought against Visa Inc. and MasterCard Inc. over credit card transaction fees. Co-counsel—both based in Little Rock, Arkansas—are Duncan Firm P.A. and Thrash Law Firm P.A.
The settlement has drawn criticism from trade associations and retailers that argue that the settlement grants credit card companies too much leeway to raise future rates, according to Bloomberg News. Continue reading










